Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia

Saved in:
Bibliographic Details
Published inLeukemia Vol. 32; no. 1; pp. 237 - 241
Main Authors Waibel, M, Vervoort, S J, Kong, I Y, Heinzel, S, Ramsbottom, K M, Martin, B P, Hawkins, E D, Johnstone, R W
Format Journal Article
LanguageEnglish
Published England Nature Publishing Group 01.01.2018
Subjects
Acute lymphoblastic leukemia
Acute lymphocytic leukemia
Care and treatment
Development and progression
Epigenesis, Genetic - drug effects
Epigenesis, Genetic - genetics
Epigenomics - methods
Genetic aspects
Health aspects
Histone Deacetylase Inhibitors - pharmacology
Humans
Innovations
Leukemia
Leukemia, T-Cell - drug therapy
Leukemia, T-Cell - genetics
Lymphatic leukemia
Lymphocytes T
Molecular targeted therapy
Notch1 protein
Panobinostat
Panobinostat - pharmacology
Patient outcomes
Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics
Receptor, Notch1 - genetics
T-Lymphocytes - drug effects
Transcription
Transcription factors
Transcription, Genetic - drug effects
Transcription, Genetic - genetics
Online AccessGet full text

Cover

More Information
Bibliography:SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Correspondence-1
ISSN:0887-6924
1476-5551
DOI:10.1038/leu.2017.282